{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:09:27Z","timestamp":1758845367104,"version":"3.44.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41375-025-02732-1","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T06:51:10Z","timestamp":1756191070000},"page":"2555-2558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid leukemia"],"prefix":"10.1038","volume":"39","author":[{"given":"Nikola","family":"Curik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Laznicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitka","family":"Krizkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2611-5848","authenticated-orcid":false,"given":"Pavla","family":"Suchankova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5848-8573","authenticated-orcid":false,"given":"Adela","family":"Vavrova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaclava","family":"Polivkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Pokorna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Semerak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2841-792X","authenticated-orcid":false,"given":"Pavel","family":"Burda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8086-9790","authenticated-orcid":false,"given":"Daniela","family":"Kuzilkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4475-2872","authenticated-orcid":false,"given":"Tomas","family":"Kalina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-0834","authenticated-orcid":false,"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7398-5555","authenticated-orcid":false,"given":"Katerina","family":"Machova Polakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"2732_CR1","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Kim DW, Cortes JE, Sasaki K, Mauro MJ, Hughes TP, et al. Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1(T315I) treated with at least 2 prior TKIs: Phase 1 final results. Leukemia. 2025;39:1114\u201323.","DOI":"10.1038\/s41375-025-02578-7"},{"key":"2732_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, R\u00e9a D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37:617\u201326.","journal-title":"Leukemia"},{"key":"2732_CR3","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/s41375-024-02278-8","volume":"38","author":"JE Cortes","year":"2024","unstructured":"Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, et al. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after 1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024;38:1522\u201333.","journal-title":"Leukemia"},{"key":"2732_CR4","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"39","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, et al. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med. 2024;39:885\u201398.","journal-title":"N Engl J Med"},{"key":"2732_CR5","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41375-024-02248-0","volume":"38","author":"N Curik","year":"2024","unstructured":"Curik N, Laznicka A, Polivkova V, Krizkova J, Pokorna E, Semerak P, et al. Combination Therapies with Ponatinib and Asciminib in a Preclinical Model of Chronic Myeloid Leukemia Blast Crisis with Compound Mutations. Leukemia. 2024;38:1415\u20138.","journal-title":"Leukemia"},{"key":"2732_CR6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543:733\u20137.","journal-title":"Nature"},{"key":"2732_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/sj.leu.2403453","volume":"19","author":"RG Piazza","year":"2005","unstructured":"Piazza RG, Magistroni V, Gasser M, Andreoni F, Galietta A, Scapozza L, et al. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib. Leukemia. 2005;19:132\u20134.","journal-title":"Leukemia"},{"key":"2732_CR8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.20517\/cdr.2021.125","volume":"5","author":"F Ong","year":"2022","unstructured":"Ong F, Kim K, Konopleva MY. Venetoclax resistance: mechanistic insights and future strategies. Cancer Drug Resist. 2022;5:380\u2013400.","journal-title":"Cancer Drug Resist"},{"key":"2732_CR9","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1084\/jem.191.6.977","volume":"191","author":"M Horita","year":"2000","unstructured":"Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med. 2000;191:977\u201384.","journal-title":"J Exp Med"},{"key":"2732_CR10","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","volume":"105","author":"KJ Aichberger","year":"2005","unstructured":"Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, et al. Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood. 2005;105:3303\u201311.","journal-title":"Blood"},{"key":"2732_CR11","doi-asserted-by":"publisher","first-page":"354ra114","DOI":"10.1126\/scitranslmed.aaf5309","volume":"8","author":"JT Leonard","year":"2016","unstructured":"Leonard JT, Rowley JS, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, et al. Targeting BCL-2 and ABL\/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Sci Transl Med. 2016;8:354ra114.","journal-title":"Sci Transl Med"},{"key":"2732_CR12","doi-asserted-by":"publisher","first-page":"e839","DOI":"10.1016\/S2352-3026(24)00250-3","volume":"11","author":"NJ Short","year":"2024","unstructured":"Short NJ, Nguyen D, Jabbour E, Senapati J, Zeng Z, Issa GC, et al. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial. Lancet Haematol. 2024;11:e839\u2013e849.","journal-title":"Lancet Haematol"},{"key":"2732_CR13","doi-asserted-by":"publisher","first-page":"E229","DOI":"10.1002\/ajh.26175","volume":"96","author":"NJ Short","year":"2021","unstructured":"Short NJ, Konopleva M, Kadia T, Kebriaei P, Daver N, Huang X, et al. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2021;96:E229\u201332.","journal-title":"Am J Hematol"},{"key":"2732_CR14","first-page":"4470","volume":"11","author":"KV Gleixner","year":"2021","unstructured":"Gleixner KV, Filik Y, Berger D, Schewzik C, Stefanzl G, Sadovnik I, et al. Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 (T315I)-compound mutations. Am J Cancer Res. 2021;11:4470\u201384.","journal-title":"Am J Cancer Res"},{"key":"2732_CR15","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1002\/ajh.27095","volume":"99","author":"I Sponseiler","year":"2024","unstructured":"Sponseiler I, Bandian AM, Pusic P, Lion T. Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph-positive leukemias. Am J Hematol. 2024;99:E9\u201311.","journal-title":"Am J Hematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02732-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02732-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02732-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:11:59Z","timestamp":1758787919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02732-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2732"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02732-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"type":"print","value":"0887-6924"},{"type":"electronic","value":"1476-5551"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KMP and AH received support by Novartis through the European Treatment and Outcome Study (EUTOS) for CML.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods and procedures were performed in accordance with the relevant guidelines and regulations. All animal-related procedures and the experimental design were reviewed and approved by the Institutional Animal Care and Use Committee and Ministry of Education, Youth and Sports of the Czech Republic (approval number MSMT-5374\/2024-4).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}